Lisata Therapeutics Enters Material Definitive Agreement
Ticker: LSTA · Form: 8-K · Filed: Oct 8, 2025 · CIK: 320017
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
Lisata Therapeutics just signed a big deal, filing an 8-K on Oct 8, 2025.
AI Summary
On October 8, 2025, Lisata Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Caladrius Biosciences, Inc., is incorporated in Delaware and has its principal executive offices in Basking Ridge, NJ.
Why It Matters
This filing indicates a significant new contract or partnership for Lisata Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, obligations, and potential outcomes of the agreement.
Key Numbers
- 001-33650 — SEC File Number (Identifies the company's filing history with the SEC.)
- 22-2343568 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Registrant
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- October 8, 2025 (date) — Date of report and earliest event
- Delaware (jurisdiction) — State of incorporation
- Basking Ridge, NJ (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Lisata Therapeutics?
The filing states that the company entered into a 'Material Definitive Agreement' but does not specify the details of the agreement itself within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated October 8, 2025.
What was Lisata Therapeutics, Inc. formerly known as?
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc.
In which state is Lisata Therapeutics, Inc. incorporated?
Lisata Therapeutics, Inc. is incorporated in Delaware.
Where are Lisata Therapeutics, Inc.'s principal executive offices located?
Lisata Therapeutics, Inc.'s principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2025-10-08 15:12:42
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
- $10.5 million — development milestone payments of up to $10.5 million in the aggregate. The Company is also e
Filing Documents
- clbs-20251008.htm (8-K) — 24KB
- 0000320017-25-000063.txt ( ) — 140KB
- clbs-20251008.xsd (EX-101.SCH) — 2KB
- clbs-20251008_lab.xml (EX-101.LAB) — 22KB
- clbs-20251008_pre.xml (EX-101.PRE) — 13KB
- clbs-20251008_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Non-Exclusive License Agreement On October 8, 2025, Lisata Therapeutics, Inc. (the "Company") entered into a worldwide Non-Exclusive License Agreement (the "Non-Exclusive License Agreement" or the "Agreement") with Catalent, Inc. ("Catalent"), pursuant to which the Company granted to Catalent, on a non-exclusive basis, certain of its intellectual property to exploit use of the Company's novel iRGD cyclic peptide, certepetide, as an antibody drug conjugate (ADC) payload as part of Catalent's SMARTag ADC platform. Under the Agreement, Catalent will assume full responsibility for research, development, and commercialization costs. Financial Terms . In connection with entering into the Non-Exclusive License Agreement, the Company is eligible to receive pre-determined development milestone payments of up to $10.5 million in the aggregate. The Company is also eligible to receive tiered revenue sharing on future sales and/or partnerships, subject to specified royalty reductions as set forth in the Agreement, as well as a portion of any sublicense consideration received from the grant of any sublicense or similar rights under any of the rights or licenses granted to Catalent under the Agreement. The Agreement will remain in effect until it expires on a product-by-product and country-by-country basis at the end of the royalty term. Termination . Either party may terminate the Agreement upon the other party's material breach, subject to specified notice and cure provisions, as well as resulting from the bankruptcy or insolvency of the other party. Catalent may also terminate the Agreement in its entirety at any time by giving the Company at least thirty (30) days prior written notice. Right of First Negotiation . In connection with the Agreement, Catalent has agreed to grant the Company a right of first negotiation ("ROFN") for a license, in the event Catalent initiates a specific, organized out-licensing process of a
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President & Chief Executive Officer Dated: October 8, 2025